Safety and Feasibility of an Endotoxemia Model

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to establish the safety and feasibility of low dose LPS administration to a small subset of humans in preparation for a larger USDA funded study examining what is the lowest effective dose of EPA + DHA (300, 600, 900 and 1,800 mg/day delivered as fish oil supplements) that significantly attenuates the inflammatory response the investigators wish to examine the effects of an endotoxemia model for inducing inflammation. Based on previous research, low dose LPS administration affects metabolism in humans with only minimal clinical effects (such as flu like illness). Therefore, each of the six subjects included in this small pilot study will receive a low dose of LPS and placebo in order to learn more about the metabolic changes that occur during administration and inflammation. The investigators hypothesis that LPS administration will elicit only minimal clinical effects (such as flu like illness) when compared to placebo (saline--water with the same amount of salt as in your blood).

Official Title
-----------------
Safety and Feasibility of an Endotoxemia Model: Pilot Study

Conditions
-----------------
Inflammation, Cardiovascular Disease

Intervention / Treatment
-----------------
* Drug: LPS (reference endotoxin, E. coli O113:H10:K:neg, manufactured under GMP)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy men and non-pregnant/lactating women between the ages of 20 and 35 years old BMI > 19.9 and < 30.0 Able to give written informed consent and willing to comply with all study- related procedures Exclusion Criteria: Previous history of heart disease or diabetes Renal Insufficiency Chronic anti-inflammatory use Systolic blood pressure < 90 Individuals currently using tobacco products or have done so in the previous 30 days Individuals taking Omega-3 fatty acid supplements or their usual intake of fish is greater than 3-4 servings per month

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: LPS<br>LPS will be injected at a dose of 0.6 ng/kg body weight through a catheter by a trained GCRC staff member involved with this study. | Drug: LPS (reference endotoxin, E. coli O113:H10:K:neg, manufactured under GMP)<br>* LPS or placebo (saline-salt water) will be injected (at approximately 7:30 am) in this catheter by a trained GCRC staff member involved with this study. Participants will not be told if they have received the drug or placebo. The LPS is a sterile solution of protein-free endotoxin which will be injected at a dose of 0.6 ng/kg body weight. Blood samples will be collected from a venous catheter for the first 12 hours and by venipuncture thereafter. Subjects will be continuously monitored by trained nursing staff for blood pressure (q 15 minutes) and body temperature (q 30 minutes), and the study will have physician oversight.<br>|
| Placebo Comparator: Saline<br>A saline solution will be injected through a catheter by a trained GCRC staff member involved with this study. | Drug: LPS (reference endotoxin, E. coli O113:H10:K:neg, manufactured under GMP)<br>* LPS or placebo (saline-salt water) will be injected (at approximately 7:30 am) in this catheter by a trained GCRC staff member involved with this study. Participants will not be told if they have received the drug or placebo. The LPS is a sterile solution of protein-free endotoxin which will be injected at a dose of 0.6 ng/kg body weight. Blood samples will be collected from a venous catheter for the first 12 hours and by venipuncture thereafter. Subjects will be continuously monitored by trained nursing staff for blood pressure (q 15 minutes) and body temperature (q 30 minutes), and the study will have physician oversight.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Inflammatory Markers |  | Baseline (before LPS administration), 1, 2, 3, 4, 6, 12, 24 hrs post LPS administration; 2, 3 and 5 days post LPS administration | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Lipid Mediators |  | 1, 2, 3 and 5 days post LPS administration | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cardiovascular disease, Inflammation, LPS, Endotoxin